Important LM bifurcation studies update
|
|
- Doris Montgomery
- 5 years ago
- Views:
Transcription
1 8 th European Bifurcation Club October Barcelona Important LM bifurcation studies update I Sheiban isheiban@yahoo.com
2 Unprotected LM Percutaneous Revascularization What is important : Assessment of left main Disease and lesion significance Procedural Challenges and Optimizing LM PCI Clinical outcomes vs surgical revascularization Present and Future: Impact on Clinical practice, Guidelines, trials.
3 Unprotected LM Percutaneous Revascularization What is important : Assessment of left main Disease and lesion significance Procedural Challenges and Optimizing LM PCI Clinical outcomes vs surgical revascularization Present and Future: Impact on Clinical practice, Guidelines, trials.
4 Left Main Lesion Assessment Angiography versus IVUS Angiographic measurements are unreliable in the assessment of intermediate LMCA lesions Visual Estimation QCA Stenosis Wide variability in visual and quantitative angiographic assessment of LMCA lesions with MLA <6 mm2 LITRO Investigators. J Am Coll Cardiol 2011;58:351-8
5 IVUS Predictors of FFR in Angiographically Intermediate LM Disease Puri et al., J A C C Cardio vasc Interv 2012 :
6 Left Main Lesion Assessment Angiography versus IVUS From a clinical perspective, MLA 6 mm2 is a safe value for deferring revascularization of the LMCA LITRO Investigators. J Am Coll Cardiol 2011;58:351-8
7 IVUS Predictors of FFR in Angiographically Intermediate LM Disease Independent determinants of FFR (N=55) Plaque rupture Minimal luminal area FFR <0.80 MLA 4.8 mm2 Sensitivity 89%, Specificity 83% FFR <0.75 MLA 4.1 mm2 Sensitivity 95%, Specificity 83% Kang et al. JACC Intvervent 2011
8 Minimal stent area threshold values for the prediction of angiographic in-stent restenosis Kang S et al. Circ Cardiovasc Interv 2011;4:
9 Frequency of Stent Underexpansion 1 vs 2 Stent Techniques 2-stent Cohort ( n = 104 ) 1-stent Cohort ( n = 289 ) 2-stent: LCX stent most frequently underexpanded and results in ISR more than half of cases 1-stent: Underexpansion is less common compared with 2 stent techniques with lower ISR *P<0.05 for comparison of LAD and POC stent underexpansion Kang S et al. Circ Cardiovasc Interv 2011;4: ;
10 Mechanisms of Luminal Loss at the LCX Ostium Morphometric Changes Pre/Post Crossover Stenting 80% of LCX ostia will have >10% reduction in MLA after crossover stenting Carina shift is principal mechanism of lumen loss; less common is plaque redistribution Narrow carina angle between LCX and LAD and wide angle between LCX and LM is associated with greater luminal loss Kang S et al. Circ Cardiovasc Interv 2011;4:
11 FFR Assessment for Angiographically Intermediate LM Disease Puri et al., J A C C Cardio vasc Interv 2012 :
12 Limitations of FFR Assessment for Angiographically Intermediate LM Disease A significant lesion at prox LAD or prox LCX can mask the true significance of the left main coronary artery lesion by compromising hyperemic flow and subsequent true maximal pressure gradient across this lesion. After treatment of the distal lesion, hyperemic blood flow through the vessel increasesn and he true fractional flow reserve (FFR) of the left main coronary artery lesion becomes apparent. Fearon WF, 8th Annual CTO Summit and Left Main Interventions Course, Puri et al., J A C C Cardio vasc Interv 2012 :
13 Unprotected LM Percutaneous Revascularization What is important : Assessment of left main Disease and lesion significance Procedural Challenges and Optimizing LM PCI Clinical outcomes vs surgical revascularization Present and Future: Impact on Clinical practice, Guidelines, trials.
14 Paclitaxel- Versus Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease ( ISAR Left Main ) 1-Year Incidence and Relative Risk of Death / MI/ TLR ISAR LEFT MAIN True bifurcation and 2-stents, but not stent technique, predictive of ISR ISAR LEFT MAIN Final kissing no additional benefit on ISR for single stent crossover or 2-stent if optimal angiographic results Tiroch et al. TCT2011; Tiroch et al. TCT 2011; Mehilli et al. JACC, 2009; 19:1760 8
15 French Left Main Taxus Registry : Five-Year Outcomes 1stent vs 2 stents D. Mylotte et al, EuroIntervention, 2012 ( ahead of publication ) Cardiac Death MACE Cardiac Death / MI / Stroke
16 Clinical and Angiographic Outcomes of Patients Treated With Everolimus- Eluting Stents or First-Generation Paclitaxel-Eluting Stents for Unprotected Left Main Disease Clinical and Angiographic Outcomes R Valenti et al, J Am Coll Cardiol. 2012;60:
17 Everolimus-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Stenosis The PRECOMBAT-2 Adjusted hazard ratios of EES in the RECOMBAT-2 study compared with SES in the historical control of PRECOMBAT study for the risk of events KIM YH et al ; J A C C CardioVac Interv 2012:
18 Left Main Surveillance Post Revascularization Lee, J.-Y. et al. J Am Coll Cardiol 2011;57:
19 PRE COMBAT Characteristics and Outcomes According to Angiographic Surveillance Overall 2 Year Repeat Revascularization: LM, 4.5%, non-lm 2.5% Park et al. NEJM 2011
20 UPLM DES Restenosis 71 Restenotic Cases (57 Focal, 14 Diffuse Pattern ISR) Timing of Presentation: 69% <1 year, 16.9% 1-2 years, 12.3% 2-3 years, 2.8% >3 years Medical Therapy: Ostial LCx, Focal ISR, Less severe % diameter stenosis, silent ischemia/stable angina CABG: LAD ISR, diffuse ISR Lee, J.-Y. et al. J Am Coll Cardiol 2011;57:
21 PRECOMBACT 2 Angiographic Restenosis in the Subgroups Stratified By Stenting Technique KIM YH et al ; J A C C CardioVac Interv 2012:
22 MAIN COMPARE Multivariate Predictors of In-Stent Restenosis *Compared with simple cross-over stenting of distal bifurcation lesions Lee et al. JACC Intervent 2011
23 Impact of Right Coronary Artery Total Occlusion on Survival Following LM PCI N=330 (24% RCA CTO) Predictors of 3-Year Mortality : RCA CTO, EuroSCORE Migliorini, A. et al. J Am Coll Cardiol 2011;58:
24 Unprotected LM Percutaneous Revascularization What is important : Assessment of left main Disease and lesion significance Procedural Challenges and Optimizing LM PCI Clinical outcomes vs surgical revascularization Present and Future: Impact on Clinical practice, Guidelines, trials.
25 ULM PCI with DES vs CABG Randomized Trial: Death or Myocardial Infarction Boudriot et al. J Am Coll Cardiol 2011;57:
26 ULM PCI with DES vs CABG Randomized Trial: Target Vessel Revascularization Boudriot et al. J Am Coll Cardiol 2011;57:
27 PRECOMBAT Death, MI, Stroke Park et al. NEJM 2011
28 PRECOMBAT Ischemia-Driven Repeat Revascularization Park et al. NEJM 2011
29 PRECOMBAT 2 Death, MI, Stroke Death from any cause Death, MI, or Stroke KIM YH et al ; J A C C CardioVac Interv 2012:
30 PRECOMBAT 2 Traget Vessel Revascularization & MACE Ischemia-driven TVR MACE KIM YH et al ; J A C C CardioVac Interv 2012:
31 Metanalysis of Randomizes Studies PCI Versus CABG in Left Main Disease D. C-apodanno, JACC 211, 54:
32 Metanalysis of Randomizes Studies PCI Versus CABG in Left Main Disease D. C-apodanno, JACC 211, 54:
33 Metanalysis of Randomizes Studies PCI Versus CABG in Left Main Disease MACCE Between PCI and CABG in the Pooled Analysis of the SYNTAX Left Main and PRECOMBAT Studies D. C-apodanno, JACC 211, 54:
34 DELTA Registry Multinational All-Comers Registry PCI = 1874 CABG= No difference between CABG and PCI in : Death, CVA and MI - An advantage of CABG over PCI in MACCE, (driven by the higher incidence of TLR/TVR in PCI Group ) Chieffo et al, JACC Cardiovasc Interv 2012 :
35 Meta-analysis of 3 Randomized Trials and 9 Observational Studies Comparing DES vs. CABG for Unprotected Left Main Coronary Artery Disease 5,079 pts treated with DES (n = 2,107) or CABG (n = 2,972), Death Death, MI, or Stroke TVR Jang J-S, et al. Am J Cardiol. 2012;Epub ahead of print
36 LM PCI vs CABG : Other Meta-analysis & Registries Meta-analysis of 5674 patients treated with percutaneous coronary intervention and drugeluting stents or coronary artery bypass graft surgery for unprotected left main coronary artery stenosis MP de Oliveira et al, Eur J Cardio thorac Surg 2012 Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials EuroIntervention 2011; publish-ahead-of-print August 2011 No difference in Death, Death / MI / CVA Meta-analysis of randomized controlled trials on the treatment of unprotected left main coronary artery disease: one-year outcomes with coronary artery bypass grafting versus percutaneous coronary artery intervention with drug-eluting stent. K Kaiimoto et al J Card Surg 2011 Meta-Analysis of Clinical Studies Comparing Coronary Artery Bypass Grafting With Percutaneous Significant Coronary increase Intervention and in Drug-Eluting TLR in PCI Stents patients in Patients With Unprotected Left Main Coronary Artery Narrowings M. Lee et al, Am J Cardiol 2010 ; 105: Comparison of one-year outcomes of percutaneous coronary intervention versus coronary artery bypass grafting in patients with unprotected left main coronary artery disease and acute coronary syndromes (from the CUSTOMIZE Registry). A. Caggegi et al, Am J Cardiol 2011 ;108(3):355-9 Stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: A meta-analysis of comparative studies H Takagi et al, J Thorac Cardiovasc Surg 2009, 137:e54-e57
37 Durable 5-Year Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stent Implantation Versus Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Lesions: Title and subtitle BreakThe Milan Experience Cardiac Death, MI, and CVA at 5 Years A. Chieffo et al, J Am Coll Cardiol Intv. 2010;3(6): doi: /j.jcin MACCE at 5 Years
38 Durable French Left Main Taxus Registry : Five-Year Outcomes Syntax Score D. Mylotte et al, EuroIntervention, 2012 ( ahead of publication ) MACE Cardiac Death Cardiac Death / MI / Stroke
39 SYNTAX Trial LM Subgroup: 1 and 4 Year Outcomes Serruys P. TCT2011
40 MACCE at 4 Years Stratified by Baseline SYNTAX Score Tercile Tercile SYNTAX Low to Intermediate Scores 0-32 Cumulative KM Event Rate ± 1.5 SE; log-rank P value Site-reported Data; ITT population Serruys P. TCT2011
41 MACCE at 4 Years Stratified by Baseline SYNTAX Score Tercile SYNTAX High Score 33 Cumulative KM Event Rate ± 1.5 SE; log-rank P value Site-reported Data; ITT population Serruys P. TCT2011
42 MACCE at 5 Years Stratified by Baseline SYNTAX Score Tercile SYNTAX High Score 33 Cumulative Event Rate (%) CABG (N=315) TAXUS (N=290) P<0.001 Overall 44.0% 26.8% Months Since Allocation Cumulative KM Event Rate ± 1.5 SE; log-rank P value CABG PCI P value Death 11.4% 19.2% CVA 3.7% 3.5% 0.80 MI 3.9% 10.1% Death, CVA or MI 17.1% 26.1% Revasc. 12.1% 30.9% <0.001 Serruys Core lab-reported P. ESC 2012 Data; ITT population
43 The simple and extremely user-friendly ACEF score can accurately identify patients undergoing PCI for coronary bifurcation lesions at high risk of early fatal or non-fatal complications, as well as long-term fatality. Biondi Zoccai G et al,eurointervention 2012; Epub ahead of print May 2012
44 SYNTAX score and Clinical SYNTAX score as predictors of very longterm clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with paclitaxel-eluting stent for coronary revascularization (SIRTAX) trial SYNTAX score and to a greater extent CSS were able to stratify risk for very long-term adverse clinical outcomes in an all-comers population receiving drug-eluting stents. Predictive accuracy for 5-year all-cause mortality was improved using CSS Girasis C et al. Eur Heart J 2011;eurheartj.ehr369
45 Global Risk Classification and Clinical SYNTAX (Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery) Score in Patients Undergoing Percutaneous or Surgical Left Main Revascularization In LM patients undergoing PCI, combined scores improve the discrimination accuracy of clinical or angiographic stand-alone tools. In LM patients undergoing CABG, the ACEF score has the best prognostic accuracy compared with other stand-alone or combined scores. The good predictive ability for PCI along with the poor predictive ability for CABG make the SYNTAX score the preferable decision-making tool in LM disease. D Capodanno et al, J Am Coll Cardiol Intv. 2011;4(3):
46 Unprotected LM Percutaneous Revascularization What is important : Assessment of left main Disease and lesion significance Procedural Challenges and Optimizing LM PCI Clinical outcomes vs surgical revascularization Present and Future: Impact on Clinical practice, Guidelines, trials.
47 Indications for CABG versus PCI in stable patients with lesions suitable for both procedures and low predicted surgical mortality In the most severe patterns of CAD, CABG appears to offer a survival advantage as well as a marked reduction in the need for repeat revascularisation.
48 2011 ACC/AHA PCI Guidelines Levine et al. J Am Coll Cardiol 2011
49 Recommendations Pertaining to Unprotected Left Main Intervention in the American College of Cardiology Foundation /American Heart Association /Society of Cardiovacular Angiography and Intervention 2011 Guidlines for PCI P. Teirstein, MJ Price, JACC 2012, 60:
50
51
52 Final Remarks Clinical trials strongly support overall no differences in death or MI, possibly lower stroke but higher TLR with PCI and these outcomes are durable over time SYNTAX Trial does encourage expansion of PCI strategy to Low SYNTAX Score patients Beside SYNTAX Score Simple Risk models can help decision making for PCI vs CABG ( i.e. ACEF ) Role for IVUS and FFR as diagnostic and guidance tools Heart Team approach for PCI and CABG is recommend in overlapping subgroups with LM disease for an optimal clinical practice
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationIntegrated Use of IVUS and FFR for LM Stenting
Integrated Use of IVUS and FFR for LM Stenting Gary S. Mintz, MD Cardiovascular Research Foundation Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease Fisher
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationLeft Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD
Left Main PCI Integrated Use of IVUS and FFR Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea Efficacy of Left
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationhigh SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy
What to do with patients with high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin San Giovanni Battista Hospital Turin / Italy Who are the patients with high SYNTAX
More informationLeft Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
More informationLeft Main Intervention: Will it become standard of care?
Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,
More informationIncidence and Treatment for LM In-Stent
Incidence and Treatment for LM In-Stent Restenosis Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology
More informationThe SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationIntracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington.
Intracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington. Medstar Washington Hospital Center Washington, DC Conflict of Interest None for this
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationCOMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil
COMMENT DEFINIR UN PLURITRONCULAIRE VISION ANGIOGRAHIQUE DU PLURITRONCULAIRE Didier Carrié CHU Toulouse Rangueil Congrès GRCI 03 Décembre 2010 Pôle Cardiovasculaire et Métabolique Avec quel œil je regarde
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationMost Patients with Elective Left Main Disease. Farrel Hellig
Most Patients with Elective Left Main Disease Should be Treated with PCI! Farrel Hellig Sunnnghill and Sunward Park Hospitals Johannesburg South Africa Everything that can be invented has been invented
More informationMise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD
Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD Columbia University Medical Center and The Cardiovascular Research Foundation, New York, USA Hôpital du Sacré-Coeur de Montréal,
More informationWhen should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER
When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER ICPS, Massy ICV-GVM La Roseraie, Aubervilliers Hôpital FOCH, Suresnes Disclosure Statement of Financial
More informationLeft Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France
Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France Background on LM stenosis 5% of patients undergoing angiography Of the myocardium 80% Bifurcation
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationLeft Main and Bifurcation Summit I. Lessons from European LM Studies
Left Main and Bifurcation Summit I Apr 29 8.56-9.09 Lessons from European LM Studies Alaide Chieffo, MD S. Raffaele Hospital, Milan, Italy Nothing to disclose regarding this presentation Lesion Location
More informationSYNTAX score before decision making! Corrado Tamburino, MD, PhD
SYNTAX score in left main - Tamburino TCT Asia Pacific Seoul, 27 April 2011 Slide 1 SYNTAX score before decision making! Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate
More informationIVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.
Left Main and Bifurcation Summit IVUS-Guided d Provisional i Stenting: ti Plaque or Carina Shift Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan College of Medicine Asan Medical Center,
More informationSide Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationMichael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Boston Scientific, Inc.- Syntax Trial Steering Committee Member- travel expenses paid by trial sponsor Maquet, Inc.- unpaid
More informationLeft Main PCI vs. CABG: Real World
Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of
More informationΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΝΟΣΟ ΣΤΕΛΕΦΟΥΣ
ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΝΟΣΟ ΣΤΕΛΕΦΟΥΣ Δ. ΤΣΙΚΑΔΕΡΗΣ MD,FESC ΘΕΣΣΑΛΟΝΙΚΗ 2012 Although LM patients population treated with stenting is usually reported as a single, homogeneous subgroup, LM disease encompasses
More informationΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική
ΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική X. ΓΡΑΪΔΗΣ Επεμβατικός καρδιολόγος, FSCAI Kλινική Euromedica-Κυανούς Σταυρός, Θεσσαλονίκη The Fear factor The two words LEFT MAIN
More informationLEFT MAIN PERCUTANEOUS CORONARY INTERVENTION. A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore
LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore Disclosures Advisory Panel, Asian Medical Board Medtronics, Abbott Vascular. Speaker-honoraria,
More informationLe# Main Interven-on: When Is It Appropriate. Femi Philip, MD Assistant Professor Of Medicine UC Davis
Le# Main Interven-on: When Is It Appropriate Femi Philip, MD Assistant Professor Of Medicine UC Davis Nil Disclosures Outline What is the LMCA? Should we revascularize severe LMCA disease? What revascularizacon
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationPrognostic Value of Gated Myocardial Perfusion SPECT
Current Use of IVUS & FFR George D. Dangas, MD, PhD, FACC, FSCAI Professor of Medicine Mount Sinai School of Medicine Prognostic Value of Gated Myocardial Perfusion SPECT 0.6% / year, Cardiac Death and
More informationPlaque Shift vs. Carina Shift Prevalence and Implication
TCTAP 2013 Fellowship Course Left Main and Bifurcation PCI: Bifurcation PCI Plaque Shift vs. Carina Shift Prevalence and Implication Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationOCT guidance for distal LM lesions
OCT guidance for distal LM lesions FRANCESCO BURZOTTA INSTITUTE OF CARDIOLOGY CATHOLIC UNIVERSITY OF THE SACRED HEART ROME, ITALY LM suitability for OCT At FU in stented LM Parodi G et al. Eurointervention
More informationAbbott Vascular. PROTOCOL EXCEL Clinical Trial
Abbott Vascular PROTOCOL Clinical Trial Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization PCI (1 st gen DES) vs. CABG for Left
More informationFFR and intravascular imaging, which of which?
FFR and intravascular imaging, which of which? Ayman Khairy MD, PhD, FESC Associate professor of Cardiovascular Medicine Vice Director of Assiut University Hospitals Assiut, Egypt Diagnostic assessment
More informationControversies in Coronary Revascularization. Atlanta CCU April 15, 2016
Controversies in Coronary Revascularization Atlanta CCU April 15, 2016 Habib Samady MD FACC FSCAI Professor of Medicine Director, Interventional Cardiology, Emory University Director, Cardiac Catheterization
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationCount Down to COMBAT
Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationKurdistan Technique for the Treatment of Unprotected Trifurcation Left Main Stem Coronary Artery Lesion: Case Report
World Journal of Cardiovascular Diseases, 2014, 4, 483-491 Published Online August 2014 in SciRes. http://www.scirp.org/journal/wjcd http://dx.doi.org/10.4236/wjcd.2014.49058 Kurdistan Technique for the
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationPost PCI functional testing and imaging: case based lessons from FFR React
Post PCI functional testing and imaging: case based lessons from FFR React Joost Daemen, MD, PhD, FESC Optics in Cardiology 2018 April 21st, 2018 10.15 10.30h Disclosure Statement of Financial Interest
More informationFractional Flow Reserve: Basics, FAME 1, FAME 2. William F. Fearon, MD Associate Professor Stanford University Medical Center
Fractional Flow Reserve: Basics, FAME 1, FAME 2 William F. Fearon, MD Associate Professor Stanford University Medical Center Conflict of Interest Advisory Board for HeartFlow Research grant from St. Jude
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationLCX. President / Director of Cardiology / New Tokyo Hospital
LCX President / Director of Cardiology / New Tokyo Hospital Professor of Department of Advanced Cardiovascular Medicine: Kumamoto University Consultant / National Cardiovascular Center / Osaka Sunao Nakamura
More informationImplications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011
Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were
More informationLong-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery
Journal of Geriatric Cardiology (2017) 14: 254 260 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationMyocardial revascularisation in multivessel disease: The value of risks scores
Myocardial revascularisation in multivessel disease: The value of risks scores ESC 2012 Marie Claude Morice, Darren Mylotte, Institut cardiovasculaire Paria Sud, Massy,France Declaration of conflict of
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationJournal of the American College of Cardiology Vol. 57, No. 12, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 57, No. 12, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.041
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationPTCA 1979: : I
The SYNTAX Message is Clear: CABG is Preferred in Complex MVD Angioplasty Summit TCTAP 2012 Seoul, Korea April 2012 David R. Holmes, MD Mayo Clinic Rochester, MN Presenter Disclosure Information David
More informationAssessing Myocardium at Risk: Applying SYNTAX
Assessing Myocardium at Risk: Applying SYNTAX Farouc Jaffer MD PhD FSCAI FACC FAHA Associate Professor of Medicine, Harvard Medical School Director, CAD Program and Chronic Total Occlusion PCI Program
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationNew-Generation Drug-Eluting Stent Experience in the Percutaneous Treatment of Unprotected Left Main Coronary Artery Disease: The NEST Registry
Original Contribution New-Generation Drug-Eluting Stent Experience in the Percutaneous Treatment of Unprotected Left Main Coronary Artery Disease: The NEST Registry Chiara Bernelli, MD 1, Alaide Chieffo,
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationR&M Solutions
PCI with DES versus CABG & syntax score Dr. Mohamed Sobhy, MD, FACC, FESC Professor of Cardiology, Alexandria University, Egypt Head of Cardiology Department President of Egyptian Society of Cardiology
More informationLeft Main Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 60, No. 17, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.01.085
More informationChapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials
Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials DEBDATTA BHATTACHARYYA AYAN KAR The incidence of angiographically significant left main stenosis described in various studies has
More informationIVUS vs FFR Debate: IVUS-Guided PCI
IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement
More informationTrue Bifurcation LM Stenosis (Medina 1,1,1) With Very Extensive Calcification: CABG Or PCI?
True Bifurcation LM Stenosis (Medina,,) With Very Extensive Calcification: CABG Or PCI? T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia PCI or CABG for Unprotected
More informationBetween Coronary Angiography and Fractional Flow Reserve
Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve Seung-Jung Park, MD., PhD. University of Ulsan, College of Medicine Asan Medical Center, Seoul, Korea Visual - Functional
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationPCIs on Intermediate Lesions NCDR Cath-PCI Registry
Practical Application Of Coronary Physiology in The Cath Lab Talal T Attar, MD, MBA, FACC PCIs on Intermediate Lesions NCDR Cath-PCI Registry Fraction of stenoses 50-70% treated with PCI without further
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationNew Insight about FFR and IVUS MLA
New Insight about FFR and IVUS MLA Can IVUS MLA Predict FFR
More informationCoronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
More informationFinal Kissing Ballooning Returns? The analysis of COBIS II registry
Final Kissing Ballooning Returns? The analysis of COBIS II registry Hyeon- Cheol Gwon Heart Vascular & Stroke Ins?tute, Samsung Medical Center Sungkyunkwan University School of Medicine Final Kissing Ballooning
More informationClinical case in perspective. Cases from Poland
Clinical case in perspective Cases from Poland Assoc. Prof. Jacek Legutko, MD, PhD President-Elect of the Association for Percutaneous Cardiovascular Interventions of the Polish Cardiac Society Institute
More information8 th European Bifurcation Club October Barcelona
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Jose Mª de la Torre Hernandez, MD, PhD, FESC Interventional Cardiology Dpt Cardiologia Valdecilla Hospital Universitario Marques de Valdecilla
More informationFFR Incorporating & Expanding it s use in Clinical Practice
FFR Incorporating & Expanding it s use in Clinical Practice Suleiman Kharabsheh, MD Consultant Invasive Cardiology Assistant professor, Alfaisal Univ. KFHI - KFSHRC Concept of FFR Maximum flow down a vessel
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationIntegrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes. Gary S. Mintz, MD Cardiovascular Research Foundation
Integrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes Gary S. Mintz, MD Cardiovascular Research Foundation COURAGE Nuclear Substudy (n=314) Death/MI according the residual ischemia (SPECT)
More informationClinical Considerations for CTO
38 RCTs Clinical Considerations for CTO 18,000 pts Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD FACC, FSCAI Director, Interventional Cardiology Research
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationWhat do the guidelines say?
Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European
More informationCoronary Artery Stenosis. Insight from MAIN-COMPARE Study
PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice
More informationLésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille
Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an
More informationINSIDE INFORMATION YOU CAN T IGNORE
INSIDE INFORMATION YOU CAN T IGNORE Volcano, the Volcano logo and SyncVision are registered trademarks of Volcano Corporation. All other trademarks set-forth are properties of their respective owners.
More informationFFR in Left Main Disease
FFR in Left Main Disease William F. Fearon, MD Associate Professor of Medicine Director, Interventional Cardiology Stanford University Medical Center Why FFR instead of IVUS? Physiologic versus anatomic
More informationFor Personal Use. Copyright HMP 2013
Original Contribution Impact of Technique and Bifurcation Anatomy on Long-Term Outcomes of PCI for Distal Unprotected Left Main Coronary Disease William Ng, MBBS 1, Robert Lundstrom, MD 1, Edward McNulty,
More informationThe Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study Five-Year Results in the French Subset René Koning, MD On behalf of the SYNTAX investigators Three-year
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationManagement of High-Risk Coronary Artery Disease
Management of High-Risk Coronary Artery Disease Jeffrey J. Popma, MD Director, Interventional Cardiology Clinical Services Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard Medical
More informationSTENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
More informationCoronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies
Review J Jpn Coron Assoc 2015; 21: 267-271 Coronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies Hiroki Shiomi, Takeshi Kimura
More information